Dr. Siegel (msiegel(at)specigen.com) has over 30 years of biopharmaceutical experience and is an executive with expertise in building companies, managing strategic alliances and organizational development. He has extensive background in biological research, new drug discovery and drug development with specific experience in venture capital fund raising (>$35 Million secured), strategic planning, competitive intelligence, business development and leadership of scientists and physicians. Dr. Siegel has successfully managed multi-disciplinary teams and executed large projects in the US and internationally. He and his colleagues have discovered and developed drugs which had annual sales in excess of four billion dollars. He served as a member of the board of directors of Delta Pharmaceuticals and is the founder and head of Rebbeson, Inc., a company that provides consulting services to entrepreneurial companies. He is the author of 170 publications and holder of 21 patents. From 1997 – 2006 he was Executive Vice President, Research & Development at Stressgen (now Nventa). From 1995 to 1997, Dr. Siegel was Vice President of Research and Development and Vice President of Science at Terrapin Technologies Inc., (now Telik). Dr. Siegel was a senior executive at Schering-Plough from 1982 to 1994 and a research scientist at Burroughs Wellcome Company from 1975 to 1982. He earned his Ph.D. at The Johns Hopkins University School of Medicine. He is a Fellow of the American Academy of Allergy, Asthma and Immunology and also a Fellow of the American Institute of Chemists.